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The neuropsychological performance of 85 women with early stage breast cancer scheduled for chemotherapy, 43 women
scheduled for endocrine therapy and/or radiotherapy and 49 healthy control subjects was assessed at baseline (T1),
postchemotherapy (or 6 months) (T2) and at 18 months (T3). Repeated measures analysis found no significant interactions or
main effect of group after controlling for age and intelligence. Using a calculation to examine performance at an individual level,
reliable decline on multiple tasks was seen in 20% of chemotherapy patients, 26% of nonchemotherapy patients and 18% of controls
at T2 (18%, 14 and 11%, respectively, at T3). Patients who had experienced a treatment-induced menopause were more likely to
show reliable decline on multiple measures at T2 (OR¼2.6, 95% confidence interval (CI) 0.823–8.266 P¼0.086). Psychological
distress, quality of life measures and self-reported cognitive failures did not impact on objective tests of cognitive function, but were
significantly associated with each other. The results show that a few women experienced objective measurable change in their
concentration and memory following standard adjuvant therapy, but the majority were either unaffected or even improve over time.
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There are various chemotherapy regimens in use to treat early
stage breast cancer, some more toxic than others, yet two women
receiving the same combination of drugs may feel completely
different during the course of their treatment. Whereas a number
of patients may experience few side effects and are able to continue
with their usual activities, others’ lives are significantly disrupted.
One of the growing concerns among patients, clinicians, neuro-
psychologists and other health professionals is that adjuvant
treatments for breast cancer may affect cognition.
It is important to recognise that the ‘cognitive dysfunction’
associated with chemotherapy is not as severe as that found with
acute amnesia or presenile dementia. Rather it is more usual for
women to complain of feelings of ‘fuzzy headedness’ or ‘mental
slowness’, sometimes described as ‘chemo-fog’ (Schagen et al,
2002). Evidence from the existing literature suggests that around
16–75% of breast cancer patients receiving high and standard dose
chemotherapy experience some degree of cognitive dysfunction
(Wieneke and Dienst, 1995; Tchen et al, 2003). Hypotheses to
explain these changes include, chemotherapy having a direct toxic
effect on the brain, changes in circulating hormones particularly in
those women who experience a treatment-induced menopause
following chemotherapy, plus fatigue, anxiety and depression
(McAllister et al, 2004).
Objective cognitive impairment is not apparent in all women,
yet subjectively many women report changes in their memory and
attention (Shilling et al, 2005a). Much of the earlier published
objective data were derived from cross-sectional studies, with only
two containing pretreatment (baseline) assessments (Wefel et al,
2004; Bender et al, 2005). In the former, a third of patients were
reported to have cognitive impairment at baseline in one or more
domains and this figure increased to 61% postchemotherapy, with
50% improving by the 12-month assessment. In the latter study,
women who received chemotherapy showed impairment on a
verbal memory measure, whereas those who had received
chemotherapy plus tamoxifen declined on visual, verbal and
working memory. Most of these differences were detected by the
18-month assessment. Both studies are limited, however, by their
small sample size (n¼18 and n¼22 at completion of study,
respectively), making meaningful conclusions difficult. A more
recent preliminary analysis of 50 chemotherapy patients with 43
healthy controls showed that at the postchemotherapy assessment,
34% of patients compared with 19% of healthy control subjects
experienced reliable cognitive decline relative to baseline perfor-
mance on multiple measures (Shilling et al, 2005a). Of interest was
that eight out of 17 (47%) of these patients experienced a
treatment-induced menopause following chemotherapy.
The potential effect of endocrine therapy on cognitive function
is more difficult to assess because of confounding factors. Women
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swith breast cancer who receive only endocrine treatment tend to
be postmenopausal and therefore older than those who receive
chemotherapy. One cross-sectional study of cognitive function in
women who participated in the Arimidex and Tamoxifen, Alone or
in Combination (ATAC) trial noted that verbal memory and
processing speed were impaired compared to healthy postmeno-
pausal women (Jenkins et al, 2004). Another study reported that
tamoxifen users consulted their physician about memory problems
more often than nonusers (Paganini-Hill and Clark, 2000) , but as
yet no study has reported longitudinal data on the effects of either
tamoxifen or aromatase inhibitors on memory and attention.
Establishing the prevalence, clinical significance and impact on
quality of life of cognitive impairment following breast cancer
treatments is important. At the moment, the literature is too
confusing to permit clear discussion. There is also some concern
that the problems have been overestimated, particularly in the light
of a recent meta-analysis (Falleti et al, 2005), which suggests that
although statistically significant, the magnitude of effect sizes
previously reported is small to moderate ranging from  0.03 to
 0.51 of a standard deviation below controls. This report presents
results from a prospective longitudinal study of the impact of
breast cancer treatments on the cognitive functioning of 128
women at three time points.
MATERIALS AND METHODS
Participants
Women with early breast cancer from hospitals across the UK were
invited to join the study following surgery but before the start of
adjuvant therapy. Exclusion criteria included advanced disease,
previous treatment for any cancer, receiving neo-adjuvant
chemotherapy, those with a previous history of stroke dementia,
degenerative disease and alcohol or drug abuse. Of 224, 153 (68%)
patients were recruited to the study; of the 69 who did not, 39 were
not interested, 11 were not eligible owing to age (475 years) or
previous treatment history and 19 did not complete the baseline
assessment before the start of treatment. The control group was
a sample of convenience made up of friends and family of the
patients and experimenters and from a local women’s group.
Of 153, 100 women were scheduled to receive adjuvant
chemotherapy and 53 to receive radiotherapy and/or endocrine
therapy or no further treatment. Data are presented on 128 breast
cancer patients (85 received chemotherapy, 43 did not) and 49
healthy controls. Of the 15 chemotherapy patients (five no longer
wanted to take part, four could not be contacted, one owing to
ill-health (unrelated), one owing to disease progression and four
had died of their disease); 10 nonchemotherapy patients (four no
longer wanted to take part, one was not contactable, two withdrew
for unrelated health reasons, two because of disease progression
and one had died of causes unknown to the authors) and three
healthy controls (one for health reasons, one for family reasons
and one emigrated) did not complete all assessments. A further six
healthy controls were excluded prior to analyses in order to bring
the groups into closer alignment for age and full-scale intelligence.
The study had local ethics committee approvals and all
participants gave full written consent.
Table 1 shows the characteristics for the three participant
groups. The nonchemotherapy group differed significantly from
the healthy controls and chemotherapy group by age (F¼22.74,
Po0.0001; F¼20.09, Po0.0001, respectively) and from the healthy
control group by years spent in full time education (F¼5.58,
P¼0.02). These differences are accounted for in the analyses.
The chemotherapy group were less likely than the other groups to
be peri- or postmenopausal at baseline (w
2¼4.90, P¼0.027;
w
2¼10.87, P¼0.001 for healthy controls and nonchemotherapy,
respectively) and the nonchemotherapy and control groups were
not more likely to have used HRT.
Table 2 details the tumour grade and type of surgery for both
patient groups and chemotherapy regimen. In total, 59% of the
chemotherapy and 14% of the nonchemotherapy patients were
lymph node positive. Time between surgery and baseline assess-
ment ranged from 21 to 83 days (mean 41.29 s.d. 13.30) in the
chemotherapy group (date of surgery missing for six patients) and
22 to 92 days in the nonchemotherapy group (mean 53.21s.d.
16.03). Eighty eight percent (75 out of 85) of the chemotherapy and
74% (32 out of 43) of the nonchemotherapy patients were seen
within 2 weeks of their second assessment and at T3, the
proportions were 91% (77 out of 85) and 86% (37 out of 43),
respectively.
At T1, 40 out of 43 (93%) nonchemotherapy patients had started
endocrine therapy; 36 received tamoxifen and four anastrozole
(one went on to have goserelin injections, six switched endocrine
treatment during the study and one ceased endocrine treatment)
and between T1 and T2 assessments, 36 out of 43 (84%) had
completed a course of radiotherapy. By T2, 20 out of 85 (23%)
chemotherapy patients had started endocrine therapy; 17 received
tamoxifen, three letrozole and by T3, this had risen to 60 (71%); 46
tamoxifen, nine letrozole and five anastrozole (two patients
switched from tamoxifen to anastrozole between assessments T2
Table 1 Age (at baseline), IQ, years in education and psychological distress
Chemotherapy (N¼85) Nonchemotherapy (N¼43) Control (N¼49)
Age (years) 51.49 (9.57) 58.93 (7.27) 51.90 (6.87)
IQ 109.89 (12.34) 111.05 (11.24) 112.04 (9.14)
Years in education 12.02 (2.60) 11.44 (1.76) 12.63 (2.86)
Menopausal status
Premenopausal 39 (46%) 7 (16%) 13 (26%)
Peri/Postmenopausal 46 (54%) 36 (84%) 36 (73%)
HRT use
Never 18 (39%) 13 (36%) 14 (39%)
Current 15 (42%)
Past 28 (61%) 23 (64%) 7 (19%)
Above threshold GHQ12 scores
a,b
T1 46(55%) 26(62%) 8(16%)
T2 43(51%) 10(24%) 9(18%)
T3 14(18%) 9 (21%) 12(24%)
aData missing from 1 chemotherapy patient at T1 and T2 and from 7 at T3.
bData missing from one nonchemotherapy patient at each time point.
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sand T3, and two received trastuzumab). Of the patients, 16 (19%)
had started a course of radiotherapy by T2 and by T3, 71 (83.5%)
had completed radiotherapy treatment. Out of 39, 32 premeno-
pausal chemotherapy patients experienced a treatment-induced
menopause.
Assessments
Cognitive assessments were made at baseline (T1), 4 weeks after
the final chemotherapy session (six months in the other groups)
(T2), and 12 months after the final chemotherapy session (18
months in the other groups) (T3).
The cognitive test battery assesses several broad areas of
cognitive function as outlined in Figure 1. The tasks used are
sensitive and have shown changes in a number of patient groups,
including those suffering with AIDS, Parkinson’s disease, head
injury, and following cardiac surgery. They can provide informa-
tion on a variety of cognitive processes including attention,
learning, memory, planning and organisational strategies.
The tests were administered in the same order following
the requirements of the Wechsler Memory Scale-III (Weschler,
1998). All participants were screened for dementia, using
the information and orientation subtest of the WMS III. The
battery of standardised neuropsychological tests is briefly
described below.
Intelligence
Intelligence was assessed using the National Adult Reading Test
(Nelson, 1991). Wechsler Adult Intelligence Scale FSIQ was
predicted from this score.
Verbal memory
WMS III logical memory part 1 and 2 indicate: immediate and
delayed recall of a short paragraph, respectively. Rey Auditory-
verbal learning test (Rey, 1964) is a word list-learning task
consisting of five verbal presentations with recall of a 15-word list.
Three scores are reported from this test: supraspan score (number
of words recalled from the first presentation of the list), total recall
score (total words recalled from the first five presentations) and
delayed recall score (total words recalled after half an hour delay).
Visual memory
Complex figure task with two alternate forms (Rey, 1941) (Taylor,
1979): copy, immediate and delayed recall of a complex geometric
figure.
Working memory
WMS III letter-number sequencing: sequences of letters and
numbers must be reordered giving numbers first in ascending
order and then letters in alphabetical order. WMS III digit span:
strings of digits must be repeated in the same and then in the
reverse order to presentation. WMS III spatial span: spatial
patterns must be reproduced first in the same and then in the
reverse order to presentation.
Executive function
The Stroop task (Golden, 1978) has three conditions, colour word
reading, colour patch naming and the interference condition in
which colour words are printed in incompatible ink colour. The
participant names the colour of the ink, requiring the inhibition of
the more salient word reading.
Processing speed and vigilance
Processing speed and vigilance are assessed using a letter
cancellation task. A composite score is calculated based on both
speed and accuracy.
Self-report measures
All participants completed the General Health Questionnaire 12
(GHQ12) and the Broadbent cognitive failures questionnaire
(Broadbent et al, 1982). The GHQ12 is a 12-item general health
measure designed to screen for probable, nonpsychotic psychiatric
disorder in community and medical settings (Goldberg and
Table 2 Treatment details for both patient groups
Chemotherapy
group (n¼85)
Nonchemotherapy
group (n¼43)
Tumour grade
Grade 1 4 16
Grade 3 31 25
Grade 3 50 2
Type of surgery
WLE 47 36
Mastectomy 26 7
Mastectomy and
reconstruction
71
Bilateral mastectomy 4
Missing 1
Type of chemotherapy
FEC
a 6 cycles 51
FEC
b 8 cycles 8
CMF 6 cycles 2
4FEC 4 docetaxel 8 cycles 3
AC 4 cycles 4
EC 6 cycles 9
4EC 4 paclitaxel 8 cycles 5
4E 4CMF 8 cycles 1
4E 4FEC 8 cycles 1
aData missing from one patient.
bData missing from one patient.
Verbal memory   WMS logical memory, immediate and delayed
 AVLT recall 1-7
Visual memory  Complex figure, copy, immediate and delayed recall 
Executive function The Stroop task
Spatial span 
Working memory  Letter/number sequencing 
Digit span
FSIQ estimate  National Adult Reading Test
Processing speed  Letter cancellation task
Self report   Cognitive failures questionnaires 
GHQ12 
FACTB, F (patients only) ES (all groups)
Figure 1 Cognitive test battery.
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sWilliams, 1988). The cognitive failures questionnaire comprises a
series of 25 questions relating to lapses in attention in everyday
life, such as forgetting what the person went into a room to do.
Questions are rated on a five-point scale ranging from 0-‘never’ to
5-‘very often’. As part of a structured interview (data to be
presented elsewhere), patients were also asked at T2 and T3
whether they had noticed any changes in their memory and
attention. Patients completed the Functional Assessment of Cancer
Therapy questionnaire (Breast) (FACT B) (Brady et al, 1997) and
the fatigue (F) subscale (Yellen et al, 1997). In addition, all
participants completed a quality of life measure of endocrine
symptoms (ES) (Fallowfield et al, 1999).
Statistical methods
The Statistical Package for the Social Sciences (SPSS) version 11.5
was used for all statistical analyses. Baseline cognitive performance
on each measure was analysed using stepwise multiple regression
with the predictor variables of treatment group, age, FSIQ,
education, psychological distress and menopausal status. Group
comparisons on cognitive performance on each measure and on
self-reported cognitive failures were made at the three time points,
using repeated measures ANOVA with group as the between-
subjects factor and time point as the within-subject factor. Where
significant main effects of group were found, any variable that had
significantly predicted baseline performance on that task was
covaried.
Such group comparisons do not identify impairment in
subgroups of the population or account for practice effects. To
examine performance at an individual level, we used the reliable
change index (RCI) with a correction for observed practice effects
on each measure (Sawrie et al, 1996). By using the method put
forward by Jacobson and Truax (1991), an RCI was calculated for
each cognitive measure using the baseline and T2 and baseline and
T3 data of the control subjects (see Appendix 1).
RESULTS
The result section is divided into changes in performance within
and between the groups over time, followed by the proportion of
individuals whose performance either improved or declined over
time for each task, compared with their baseline performance. The
results from these objective cognitive tasks are then compared with
the patients’ subjective measures of changes in psychological
distress, memory and concentration and quality of life.
Group comparisons
Baseline (T1) Combinations of education, age and FSIQ con-
sistently predicted cognitive performance (see Table 3). Treatment
group failed to significantly predict cognitive performance on any
of the 14 measures independently of factors such as age, education
and FSIQ, as did menopausal status and GHQ12 scores. In all cases,
the regression was a poor fit describing between 8 and 22% of the
variance (R
2adj between 8 and 20%), but the overall relationship
was significant (Po0.0001) in all cases.
Repeated measures ANOVA Repeated measures ANOVAs with
group (chemo vs nonchemo vs control) as the between-subject
factor and time point (T1 vs T2 vs T3) as the within-subject factor
were conducted for each of the 14 cognitive measures. In a number
of cases, the assumption of sphericity was violated. In all cases E
was greater than 0.75, so the Huynh and Feldt correction was used.
Bonferroni was used for post hoc comparisons where sphericity
was violated; Games-Howell was used where sphericity was not
violated.
Table 3 Results of regression analyses on baseline scores shows that combinations of education, age and Full Scale Intelligence Quotient (FSIQ)
consistently predicted performance on the cognitive tasks
TASK R
2 R
2adj F P Factor b tP
Letter cancellation 0.152 0.137 10.188 o0.0001 Education 0.489 1.889 0.061
Age  0.171  2.734 0.007
FSIQ 0.136 2.442 0.016
Auditory verbal learning task (AVLT) 0.109 0.98 10.444 o0.0001 Age  0.049  3.505 0.001
Supraspan FSIQ 0.033 3.006 0.003
AVLT total 0.204 0.194 21.862 o0.0001 Age  0.35  5.319 o0.0001
FSIQ 0.208 4.04 o0.0001
AVLT delayed 0.146 0.136 14.563 o0.0001 Education 0.304 0.085 o0.0001
Age  0.077 0.024 0.002
Complex figure immediate 0.112 0.101 10.689 o0.0001 Age  0.209  3.939 o0.0001
FSIQ 0.104 2.509 0.013
Complex figure delayed 0.139 0.129 13.789 o0.0001 Age  0.201  4.169 o0.0001
FSIQ 0.124 3.28 0.001
Story immediate recall 0.206 0.196 22.125 o0.0001 FSIQ 0.122 5.24 o0.0001
Age  0.125  4.207 o0.0001
Story delayed recall 0.209 0.2 22.593 o0.0001 FSIQ 0.121 5.141 o0.0001
Age  0.134  4.438 o0.0001
Letter/number sequencing 0.223 0.209 16.258 o0.0001 FSIQ 0.102 6.033 o0.0001
Age  0.075  3.94 o0.0001
Education  0.179  2.279 0.024
Digit span forward 0.212 0.207 46.278 o0.0001 FSIQ 0.094 6.803 o0.0001
Digit span backwards 0.221 0.212 24.205 o0.0001 FSIQ 0.086 6.593 o0.0001
Age  0.039  0.2363 0.019
Spatial span forwards 0.118 0.108 11.453 o0.0001 Age  0.053  3.863 o0.0001
FSIQ 0.031 2.906 0.004
Spatial span backwards 0.216 0.202 15.609 o0.0001 Education 0.15 2.663 0.008
Age  0.052  3.77 o0.0001
FSIQ 0.028 2.318 0.022
Stroop 0.084 0.079 15.722 o0.0001 Education 0.793 3.965 o0.0001
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sNone of the measures showed a significant group time point
interaction. Six measures showed a significant main effect of
time, with performance increasing linearly (letter cancellation
F¼15.57 Po0.0001; AVLT supraspan F¼4.083, P¼0.018; AVLT
total F¼3.175, P¼0.043; complex figure immediate recall
F¼6.99¼0.002; complex figure delayed recall F¼10.69,
Po0.0001; digit span backwards F¼3.53, P¼0.031 and Stroop
F¼4.29, P¼0.014).
Five measures showed a significant main effect of group: AVLT
supraspan (F¼5.60, P¼0.004); complex figure immediate recall
(F¼3.79 P¼0.024); complex figure delayed recall (F¼3.55,
P¼0.031); spatial span forwards (F¼3.72, P¼0.026) and spatial
span backwards (F¼3.71, P¼0.026). Post hoc comparisons
revealed significant differences were between the nonchemother-
apy patient group and the healthy control group (P¼0.004; 0.021;
0.026; 0.039; 0.036 respectively). These five repeated measures
ANOVAs were recalculated covarying factors that were significant
predictors of performance at baseline (age, FSIQ and in the case of
spatial span backwards this also included years in education).
Group ceased to be a significant main effect after covarying these
baseline predictor variables, although a trend towards an effect of
group remained for AVLT supraspan (F¼2.68, P¼0.071).
Reliable change analyses The proportion of each group showing
reliable decline or reliable improvement for each task is shown for
both time points in Table 4. Group did not significantly predict
reliable decline on any individual measure at either time with the
exception of spatial span forward at T2, which was more common
in the healthy control group than in either patient group (overall
w
2¼13.44, P¼0.001). Those who showed reliable decline were not
significantly older, or less intelligent; nor were they more likely to
have above threshold GHQ12 scores. Reliable improvement on two
or more measures was not more common in any one group at T2,
but at T3 multiple improvement was more likely in the patient
groups, OR 2.78 (w
2¼4.925, P¼0.02) and 2.54 (w
2, n.s.) for
chemotherapy and nonchemotherapy, respectively Table 5.
The effect of endocrine therapy It was not possible to compare the
effects of endocrine therapy on cognitive performance within the
nonchemotherapy group as 91% were receiving endocrine therapy.
Within the chemotherapy group, performance did not differ
significantly on any measure between those who did or did not
receive endocrine therapy at T3 (N¼60 and 25, respectively).
Psychological distress (GHQ12) Table 1 shows the proportion of
each group with above threshold GHQ12 scores, suggesting
probable psychiatric morbidity at each time point. In both patient
groups, rates of psychological distress were above 50% at baseline.
In the nonchemotherapy group, this dropped significantly by T2 to
levels approximately the same as the control group, where it
remained at T3. In the chemotherapy group psychological distress
remained high at T2 and did not drop to control levels until T3.
Self-reported cognitive failures Patients and controls reported
similar numbers of cognitive failures in everyday life on the
Broadbent Cognitive Failures questionnaire. Repeated measures
ANOVA with time point as the within-subject factor and group as
the between-subject factor found no significant main effect of
group but a significant main effect of time point (F¼16.02,
Po0.0001) and a significant interaction (F¼4.26, P¼0.016). The
scores show a different pattern for the three groups. In the healthy
control group, scores were stable across the three time points
(mean score 40.14, 40.41 and 40.08). In the chemotherapy group
mean, scores were initially lower than in the healthy control group
(37.95), rising significantly at T2 to 43.13 (t¼ 4.24, Po0.0001)
before dropping to 41.56. Finally, the nonchemotherapy group also
had mean scores lower than the healthy control group at baseline
(37.64) but showed a steady increase over time with an overall
Table 4 Percentage of each group showing reliable decline, reliable improvement or no change for each task at T2 (T3)
Chemotherapy group (n¼85) Nonchemotherapy group (n¼43) Healthy control group (n¼49)
Decline Improve Stable Decline Improve Stable Decline Improve Stable
Letter
a cancellation 4 (6) 2 (2) 94 (92) 0 (9) 5 (5) 95 (86) 4 (2) 4 (4) 92 (94)
AVLT supraspan 15 (14) 10 (9) 75 (77) 9 (5) 9 (5) 82 (90) 8 (6) 16 (6) 76 (88)
AVLT total 12 (12) 4 (6) 84 (82) 9 (16) 5 (12) 86 (72) 6 (8) 4 (6) 90 (86)
AVLT delayed 5 (5) 2 (5) 93 (90) 2 (0) 12 (12) 86 (88) 6 (0) 4 (6) 90 (94)
Complex figure imm.
b,c 5 (5) 8 (12) 87 (83) 12 (2) 5 (13) 84 (85) 4 (4) 2 (4) 94 (92)
Complex figure del.
d 7 (1) 7 (12) 86 (87) 5 (2) 2 (2) 93 (96) 2 (0) 4 (6) 94 (94)
Story imm. 8 (11) 11 (12) 81 (77) 14 (7) 14 (14) 72 (79) 6 (8) 6 (4) 88 (88)
Story del. 10 (1) 15 (8) 75 (91) 9 (5) 9 (5) 82 (90) 2 (2) 4 (4) 94 (94)
Letter/number sequencing 5 (10) 3 (5) 92 (85) 14 (9) 0 (2) 86 (89) 6 (8) 8 (4) 86 (88)
Digit span forward 6 (4) 3 (2 ) 91 (94) 7 (2) 0 (5) 93 (93) 10 (4) 2 (4) 88 (92)
Digit span backwards 2 (5) 0 (3) 98 (92) 7 (5) 0 (9) 93 (86) 8 (2) 4 (2) 88 (96)
Spatial span forwards 0 (2) 3 (18) 97 (80) 0 (7) 5 (9) 95 (84) 10 (6) 4 (0) 86 (94)
Spatial span backwards 5 (4) 3 (1) 92 (95) 5 (0) 7 (2) 88 (98) 2 (6) 8 (2) 90 (92)
Stroop
e,f 11 (4) 5 (8) 84 (88) 9 (7) 2 (9) 88 (84) 6 (4) 6 (4) 88 (92)
Missing data.
aTime 3; data missing from one chemotherapy patient and one nonchemotherapy patient.
bTime 2; data missing from one healthy control.
cTime 3; data missing
from one chemotherapy patient and one healthy control.
dTime 3; data missing from one chemotherapy patient.
eTime 2; data missing from one chemotherapy patient and one
healthy control.
fTime 3; data missing from two chemotherapy patients and one healthy control.
Table 5 Extent of reliable change at T2 and T3
T2 T3
Chemo Nonchemo Control Chemo Nonchemo control
Decline on X2 measures 17 20% 11 25.6% 9 18.4% 15 18.1% 6 14.3% 5 10.6%
Improve on X2 measures 19 22.4% 7 16.3% 8 16.3% 27 32.1% 13 30.2% 7 14.6%
Adjuvant therapy and cognition
V Jenkins et al
832
British Journal of Cancer (2006) 94(6), 828–834 & 2006 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
ssignificant increase (F¼13.34, P¼0.001) but no significant
increase between consecutive time points.
At each time point, participants with above threshold GHQ12
scores reported significantly more cognitive failures than those
with below threshold scores (t¼3.397, P¼0.001; t¼3.81,
Po0.0001; t¼3.22, P¼0.002), but self-reported cognitive failures
did not significantly correlate with objective cognitive test scores.
At interview, the majority of the chemotherapy group reported
that they had noticed changes in their memory (83%) and
concentration (80%) at T2. This fell to 60 and 45%, respectively,
by T3. The incidence was lower in the nonchemotherapy group
with 45 and 38%, respectively, noticing changes in memory and
concentration at T2. However, at T3 the proportion reporting
memory problems had risen to 59%, although concentration
problems remained lower at 37%. Reporting of problems was
significantly associated with GHQ12 threshold scores but not with
objective measures of cognition.
Quality of life and cognitive function There was no significant
main effect between the two patient groups on the fatigue subscale;
however, there was a significant interaction (F¼3.91, P¼0.021)
and a significant main effect of time (F¼5.99, P¼0.03). Although
fatigue levels in the nonchemotherapy group were stable at all
three times, the chemotherapy group showed a significant increase
in symptoms immediately after chemotherapy (t¼3.66,
Po0.0001), with a significant improvement from baseline 1 year
later (t¼4.75, Po0.0001). A similar pattern was seen on the
FACT-B scores (F¼10.24, P¼0.0001, F¼3.43, P¼0.034 for time
and interaction, respectively). Scores in the nonchemotherapy
group were generally higher and stable at the three times, whereas
the chemotherapy group showed a significant improvement in
quality of life at T3 (t¼5.70, Po0.0001). Scores on the ES scale (all
three participant groups) showed a significant main effect of group
(F¼3.27, P¼0.041), time (F¼18.48, Po0.0001) and an interac-
tion (F¼9.89, Po0.0001). Post hoc tests found no significant
group differences at any time point. In both patient groups,
endocrine symptoms increased significantly between T1 and T2
(t¼6.97, P¼0.0001, t¼3.83, Po 0.0001 chemotherapy and
nonchemotherapy groups, respectively) and remained high at T3.
Quality of life measures did not correlate with individual test
scores at baseline, T2 or T3. Quality of life scores were not
significantly lower in those participants with reliable decline on
multiple measures at T2 or T3.
HRT use and treatment-induced menopause The potential effect
of HRT use on cognitive function was examined across groups (the
groups were balanced on the proportion of postmenopausal
women who had taken HRT). There was no significant main
effect of HRT use (never vs current or past) on any cognitive
measure at baseline and HRT use was not associated with reliable
decline on multiple measures at T2 or T3. Patients who
experienced a treatment-induced menopause (TIM) following
chemotherapy treatment (N¼32 out of 39) were compared with
those in the chemotherapy group who were postmenopausal at
baseline. Those who had TIM were more likely to show reliable
decline on multiple measures at T2 (OR¼2.6, 95% confidence
interval (CI) 0.823–8.266, P¼0.086) and 1.51 times as likely at T3
(95% CI 0.405–3.922, P¼0.145). These were not more likely to
have above threshold GHQ12 scores at either time point or to
report lower quality of life.
DISCUSSION
This study benefits from both a longitudinal design and the ability
to control for individual difference factors such as intelligence, age
and education to permit a realistic appraisal of the extent of
cognitive impairment after treatment for early stage breast cancer.
Little convincing evidence was found to suggest that there is
measurable and meaningful impairment for the vast majority of
women in the UK who receive standard adjuvant treatments for
breast cancer.
The most reliable predictor of performance on the tasks was age,
intelligence and years in education. Chemotherapy, endocrine
therapy, HRT use, quality of life and level of psychological distress
were not associated with performance at a group or individual
level. Although reliable decline on multiple measures was more
common in the patient groups than in the healthy control group,
there was not a significant association at either time point. More
importantly, the majority of patients either showed no change or
an improvement in performance. Many studies that classify
patients as impaired or not, established on ‘failing’ a number of
tests at a given criteria, are cross sectional and do not account for a
change in cognitive function and other factors such as practice
effects. Some of the issues relating to classifying cognitive
impairment, using different statistical methods are detailed
elsewhere (Shilling et al, 2005b).
A timely meta-analysis warns of the previous overinterpretation
of apparent cognitive impairment in patients receiving chemo-
therapy. Although statistically significant cognitive impairment
was found in the analysis, the magnitude of the impairment was
small to moderate, with patients treated with chemotherapy
performing better than the comparison group on some tests
(Falleti et al, 2005). One possible reason why relatively little
impairment was found in our chemotherapy group may be that the
majority received relatively low dose FEC. This would support
findings by van Dam et al (1998) who found no differences
between patients receiving FEC (and also tamoxifen) and those not
treated with systemic adjuvant therapy.
The level of psychological morbidity in the patient groups in our
study was high at baseline but similar to that reported in the
literature (Burgess et al, 2005). A difference between groups
became apparent at the second assessment, with the chemotherapy
patients maintaining high levels of psychological distress. The
disparity between groups probably reflected the stage of treatment
that the patients had reached. The nonchemotherapy patients had
completed their radiotherapy treatment by several months,
whereas many of the chemotherapy patients were waiting to
begin. In common with other studies, psychological distress,
quality of life measures and self-reported cognitive failures did not
impact on objective tests of cognitive function, but were
significantly associated with each other.
The hypothesis that women may experience greater cognitive
decline if treatment results in a sudden premature menopause was
supported, albeit weakly, probably due to the small sample size;
these women were 2.6 times more likely to show reliable decline on
multiple measures, following chemotherapy. A sudden menopause
brings all the accompanying endocrine symptoms, for example hot
flushes, night sweats and difficulty in sleeping. An accumulation of
these may have interfered with a woman’s ability to concentrate on
the memory and attention tasks. The suggestion that an increase in
individual endocrine symptoms may contribute significantly to
cognitive performance was supported by the preliminary analysis
of 50 of the present chemotherapy patients and 43 healthy controls
(Shilling et al, 2005a). The most significant factor to account for
the difference between the current data and that previously
reported was that 52% of the patients in the preliminary analyses
were premenopausal at baseline, compared to 36% in the present
data set and these women were significantly more likely to
experience a treatment-induced menopause (OR 3.12, P¼0.016).
In summary, the results from this study suggest that only a small
proportion of women receiving adjuvant treatments for breast
cancer experience objective measurable change in their concentra-
tion and memory. It is reassuring that the majority are either
unaffected or even improve over time, but such results are rarely
emphasised in publication. The group of women who appear to be
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those who experience a treatment-induced menopause, particu-
larly in the initial period following chemotherapy. Future studies
may like to focus on this group of women receiving treatments that
induce early menopause, including LHRH therapy. This would also
help clarify whether it is a reduction in oestrogen producing severe
endocrine symptoms that interferes with attending to stimuli and
therefore constrains memory processing, or chemotherapy treat-
ment per se.
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Appendix 1
The RCI was calculated as follows:
The test–retest reliability coefficient (rxx) was computed for
each measure. The standard error of measurement (SEm) was
calculated by:
SEm ¼ SD1
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
½1   rxx 
p   
;
where SD1 is the s.d. of the baseline score. The standard error of
the difference (SEdiff) was calculated by:
SEdiff¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
½2ðSEmÞ
2 
q
:
The standard error of the difference describes the spread of
distribution of change scores that would be expected if no change
occurred.
To establish a 90% RC confidence interval, the SEdiff was
multiplied by 71.64 s.d. (Kneebone et al, 1998). These cutoff
points were corrected for practice effects (Sawrie et al, 1996). The
practice effect for each variable is the mean difference between the
follow-up and baseline scores. Thus, for each variable, an RC 90%
confidence interval was calculated by:
RCinterval ¼ð SEdiffÞ ð   1:64Þþpracticeeffect:
For each participant, a difference score was calculated represent-
ing the performance difference on each measure (T2 – T1). If this
score fell outside the RC interval, a statistically significant change
in performance on this measure was considered to have occurred.
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